Post-Conference Perspectives: Urothelial Carcinoma 2022 Year in Review - Episode 2

Neoadjuvant Chemotherapy as Standard-of-Care for Muscle-Invasive Urothelial Carcinoma

October 5, 2022

Jeanny B. Aragon-Ching, MD, FACP, Srikala Sridhar, MD, MSc, FRCPC

Srikala Sridhar, MD, MSc, FRCPC, explains the importance of neoadjuvant cisplatin-based chemotherapy and why bladder-sparing treatments should be considered for all patient populations.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Incidence and Risk Factors for Urothelial Carcinoma

Now Viewing

EP. 2: Neoadjuvant Chemotherapy as Standard-of-Care for Muscle-Invasive Urothelial Carcinoma

EP. 3: Neoadjuvant Chemotherapy in Urothelial Carcinoma: The CHECKMATE-274 Trial

EP. 4: Neoadjuvant Chemotherapy in Urothelial Carcinoma: The IMvigor010 Study

EP. 5: Treatment Options for Frontline Metastatic Urothelial Carcinoma

EP. 6: Outcomes of the JAVELIN Bladder 100 Trial

EP. 7: Metastatic Urothelial Carcinoma Treatment after Disease Progression on Avelumab

EP. 8: Key Trial Data in Urothelial Carcinoma Treatment from ESMO 2022